Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $14.00 per share. The shares of Enanta’s common stock will trade on the NASDAQ Global Select Market under the symbol "ENTA" beginning on March 21, 2013. All of the shares of common stock are being offered by Enanta. In addition, Enanta has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on March 26, 2013, subject to customary closing conditions.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. Leerink Swann LLC and JMP Securities LLC are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 20, 2013.
The offering will be made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by calling toll-free (866) 803-9204; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by calling toll-free (800) 221-1037, or by emailing firstname.lastname@example.org.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.